S1PR2 and Cognitive impairment: The aims of this work were to (1) assess if blocking S1PR2 in vivo with the antagonist JTE-013 reverses cognitive impairment in hyperammonemic rats; (2) assess if this is associated with a reversal of alterations in the membrane expression of AMPA and NMDA receptors in the hippocampus; (3) assess if this is associated with a reversal of glial activation and neuroinflammation; (4) identify pathways by which enhanced S1PR2 activation induces neuroinflammation in the hippocampus of hyperammonemic rats.